Clinical Trial Update: Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD) [Phase 2]

View source ↗

Summary

Phase 2 repeat-dose study of GSK3772847 in moderate to severe asthma with allergic fungal airway disease was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK3772847

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2020-10-23